Publicaciones en colaboración con investigadores/as de Instituto de Investigación Biomédica de Salamanca (10)

2023

  1. Renal Sympathetic Hyperactivity in Diabetes Is Modulated by 5-HT1D Receptor Activation via NO Pathway

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

2022

  1. CRISPR/Cas9‐Directed Gene Trap Constitutes a Selection System for Corrected BCR/ABL Leukemic Cells in CML

    International Journal of Molecular Sciences, Vol. 23, Núm. 12

  2. Effect of sarpogrelate treatment on 5-HT modulation of vascular sympathetic innervation and platelet activity in diabetic rats

    Biomedicine and Pharmacotherapy, Vol. 153

  3. Fluoxetine Treatment Decreases Cardiac Vagal Input and Alters the Serotonergic Modulation of the Parasympathetic Outflow in Diabetic Rats

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

  4. Oral fluoxetine treatment changes serotonergic sympatho-regulation in experimental type 1 diabetes

    Life Sciences, Vol. 293

2021

  1. CRISPR-Cas9 Technology as a Tool to Target Gene Drivers in Cancer: Proof of Concept and New Opportunities to Treat Chronic Myeloid Leukemia

    CRISPR Journal, Vol. 4, Núm. 4, pp. 519-535

  2. Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment

    Journal of Pharmacological Sciences, Vol. 147, Núm. 1, pp. 48-57

2020

  1. Role of peripheral 5-HT5A receptors in 5-HT-induced cardiac sympatho-inhibition in type 1 diabetic rats

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Fluoxetine oral treatment discloses 5-HT 1D receptor as vagoinhibitor of the cardiac cholinergic neurotransmission in rat

    Canadian Journal of Physiology and Pharmacology, Vol. 97, Núm. 2, pp. 90-98

2017

  1. The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia

    Oncotarget, Vol. 8, Núm. 16, pp. 26027-26040